Search company, investor...

Cardiac Pathways

Founded Year

1991

Stage

Acquired | Acquired

Total Raised

$67M

Valuation

$0000 

Revenue

$0000 

About Cardiac Pathways

Cardiac Pathways manufactures minimally invasive systems used by electrophysiologists to diagnose and treat cardiac tachyarrhythmias, which if untreated can cause palpitations, fainting, and sudden cardiac arrest. Cardiac Pathways' products consist principally of systems for performing ablation treatment and for diagnostic mapping.

Headquarters Location

995 Benecia Avenue

Sunnyvale, California, 94085,

United States

408-737-0505

Missing: Cardiac Pathways's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cardiac Pathways's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Cardiac Pathways Frequently Asked Questions (FAQ)

  • When was Cardiac Pathways founded?

    Cardiac Pathways was founded in 1991.

  • Where is Cardiac Pathways's headquarters?

    Cardiac Pathways's headquarters is located at 995 Benecia Avenue, Sunnyvale.

  • What is Cardiac Pathways's latest funding round?

    Cardiac Pathways's latest funding round is Acquired.

  • How much did Cardiac Pathways raise?

    Cardiac Pathways raised a total of $67M.

  • Who are the investors of Cardiac Pathways?

    Investors of Cardiac Pathways include Boston Scientific, Trellis Health Ventures, Van Wagoner Capital Management, Scale Venture Partners, State of Wisconsin Investment Board and 6 more.

  • Who are Cardiac Pathways's competitors?

    Competitors of Cardiac Pathways include Biocytogen, PPD, Corassist Cardiovascular, ADVOS, BioWave, Cardiva Medical, Salutaris Medical Devices, Eiger BioPharmaceuticals, DFine, Merus and 49 more.

Compare Cardiac Pathways to Competitors

A
Antivirals

Antivirals is engaged in the discovery of agents that inhibit replication of human pathogenic viruses.

S
Sonivate Medical

Sonivate Medical develops and manufactures technologies to reduce healthcare cost and expand access to diagnostic imaging. The SonicEye is a fingertip-mounted ultrasound probe that enables imaging while leaving both hands free to do work with simultaneous tactile feedback.

A
Acorn Cardiovascular

Acorn Cardiovascular is a medical device company pursuing treatments for patients with heart failure. Acorn

C
Cleveland Heart

Cleveland Heart has partnered with the Cleveland Clinic to develop the next generation of mechanical cardiac circulatory assist devices with the potential to provide a complete range of treatment options for patients suffering from irreversible end-stage heart failure.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

P
PharmSelex

PharmaSelex (fka:GPC-Rx) focuses on the structure prediction of G-protein coupled receptors (GPCRs) to develop new GPCR-targeting drugs with reduced toxicity and enhanced selectivity. GPCRs are cell surface receptors that transmit chemical messages across the cell membrane. GPCRs have a complex structure that spans the cellular membrane seven times and is therefore difficult to predict. Due to their mediation of numerous critical physiological functions, GPCRs are involved in major disease areas including cardiovascular, metabolic, neurodegenerative, psychiatric, cancer, and infectious diseases. To facilitate the development of GPCR-targeting drugs, GPC-Rx aims to predict the structures of apo and ligand-bound GPCRs. The structure of GPCRs will permit rational design and optimization of drug candidates of many disease targets. GPC-Rx's technology was developed in the laboratory of Dr. William Goddard Ph.D. at California Institute of Technology. The Goddard group has established and validated methods to generate 3D-structures of GPCRs and their complexes with known ligands.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.